The approval makes Biocon's pertuzumab the first biosimilar to receive EC marketing authorisation under the European Medicines Agency's (EMA) new tailored clinical approach. New Delhi, Nov 18 (PTI) Biopharmaceutical firm Biocon Ltd has received marketing authorisation from the European Commission (EC) for Pebrilzo, its pertuzumab biosimilar, to treat HER2-positive. Biocon’s pertuzumab gets marketing authorization in EU, first biosimilar approved under new tailored clinical approach: Our Bureau, Bengaluru Wednesday, November 18, 2026,.